Nanosponges: A novel class of drug delivery system - Review

Journal of Pharmacy and Pharmaceutical Sciences

Volumn 15, Issue 1, 2012, Pages 103-111

  Subramanian, Selvamuthukumar ^a   Singireddy, Anandam ^a   Krishnamoorthy, Kannan ^a   Rajappan, Manavalan ^a  

^a ANNAMALAI UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; CAMPTOTHECIN; DEXAMETHASONE; ECONAZOLE; ITRACONAZOLE; NANOPARTICLE; NANOSPONGE; PACLITAXEL; RESVERATROL; TAMOXIFEN; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

AQUEOUS SOLUTION; ARTICLE; BIOACCUMULATION; BIOCATALYST; BRAIN TUMOR; BREAST CANCER; CARDIOVASCULAR DISEASE; COMPLEX FORMATION; CRYSTAL STRUCTURE; DERMATITIS; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG SOLUBILITY; ECHOGRAPHY; FEVER; GONORRHEA; HYDROPHILICITY; HYPERLIPIDEMIA; INFLAMMATION; INFRARED SPECTROSCOPY; INTERMETHOD COMPARISON; LIPOPHILICITY; MICROSCOPY; MOLECULAR WEIGHT; NANOENCAPSULATION; NANOFABRICATION; NEOPLASM; NONHUMAN; PARTICLE SIZE; POROSITY; PREDICTION; QUANTITATIVE ANALYSIS; SURFACE PROPERTY; TEMPERATURE DEPENDENCE; THERMAL ANALYSIS; THIN LAYER CHROMATOGRAPHY; VIRUS INFECTION; X RAY DIFFRACTION; ZETA POTENTIAL;

EID: 84856776186     PISSN: None     EISSN: 14821826     Source Type: Journal    
DOI: 10.18433/j3k308     Document Type: Article

References (68)

1. Trotta F, Cavalli R, Tumiatti W, Zerbinati O, Rogero C, Vallero R. Ultrasound-assisted synthesis of Cyclodextrin-based nanosponges. EP 1 786 841 B1; 2007
2. David F. Nanosponge drug delivery system more effective than direct injection. www.physorg.com 01.06.2010, accessed on 20.12.2011
3. Trotta F, Tumiatti V, Cavalli R, Rogero C, Mognetti B, Berta G. Cyclodextrin-based nanosponges as a vehicle for Antitumoral drugs. WO 2009/003656 A1; 2009
4. Liang L, De-Pei L, Chih-Chuan L. Optimizing the delivery systems of chimeric RNA. DNA oligonucleotides beyond general oligonucleotide transfer. Eur. J. Biochem. 2002; 269: 5753-5758
5. Jenny A, Merima P, Alberto F, Francesco T. Role of β- cyclodextrin nanosponges in polypropylene photooxidation. Carbohydrate Polymers, 2011; 86: 127-135
6. Leslie Z. Benet., BCS and BDDCS. Bioavailability and Bioequivalence: Focus on Physiological Factors and Variability. Department of biopharmaceutical sciences, University of California, San Francisco, USA, 2007
7. Renuka S, Roderick BW, Kamla P. Evaluation of the kinetics and mechanism of drug release from Econazole Nitrate nanosponge loaded carbapol hydrogel. Ind J Parm Edu Res, 2011; 45(1): 25-31
8. Renuka S, Kamla P. Polymeric nanosponges as an alternative carrier for improved retention of econazole nitrate onto the skin through topical hydrogel formulation Pharm Dev Technol. 2011; 16(4):367-376
9. Torne SJ, Ansari KA, Vavia PR, Trotta F, Cavalli R. Enhanced oral Paclitaxel bioavailability after administration of Paclitaxel loaded nanosponges Drug Delivery, 2010; 17(6):419-425
10. Ansari KA, Torne SJ, Vavia PR, Trotta F, Cavalli R. Paclitaxel loaded nanosponges: in-vitro characterization and cytotoxicity study on MCF-7 cell line culture. Curr Drug Deliv, 2011; 8(2):194-202
11. Shankar S, Linda P, Loredana S, Francesco T, Pradeep V, Dino A, Michele T, Gianpaolo Z, Roberta C. Cyclodextrin-based nanosponges encapsulating camptothecin: Physicochemical characterization, stability and cytotoxicity. Eur J Pharm Biopharm, 2010; 74: 193-201
12. Rosalba M, Roberta C, Roberto F, Chiara D, Piergiorgio P, Leigh E, Li S, Roberto P. Antitumor activity of nanosponge-encapsulated Camptotechin in human prostate tumors. Cancer Res,2011; 71:4431
13. Khalid AA, Pradeep RV, Francesco T, Roberta C Cyclodextrin-based nanosponges for delivery of Resveratrol: In Vitro characterisation, stability, cytotoxicity and permeation Study AAPS PharmSciTech, 2011; 12(1): 279-286
14. William K, Benjamin S, Eva H. Synthesis and Characterization of Nanosponges for Drug Delivery and Cancer Treatment www.Vanderbilt.edu accessed on 20.12.2011
15. Shankar S, Vavia PR, Francesco T, Satyen T Formulation of Betacyclodextrin based nanosponges of Itraconazole. J Incl Phenom Macrocycl Chem, 2007; 57: 89-94
16. Lala R, Thorat A, Gargote C. Current trends in β- cyclodextrin based drug delivery systems. Int J Res Ayur Pharm, 2011; 2(5): 1520-1526
17. Isabelle A, Christine V, Helene C, Elias F, Patrick C. Spongelike Alginate Nanoparticles as a new potential system for the delivery of Antisense Oligonucleotides. Antisense and Nucleic Acid Drug Development, 1999; 9(3): 301-312
18. Gilardi G, Trota F, Cavalli R, Ferruti P, Ranucci E, Di Nardo G, Roggero C, Tumiatti V Cyclodextrin nanosponges as carrier for biocatalysts, and in the delivery and release of enzymes, proteins, vaccines and antibodies WO2009149883 A1; 2009
19. Trotta F, Tumiatti W. Cross-linked polymers based on cyclodextrins for removing polluting agents. WO 03/085002 A1; 2003
20. Wong VN, Fernando G, Wagner AR, Zhang J, Kinsel GR, Zauscher S, Dyer DJ. Separation of peptides with polyionic nanosponges for MALDIMS analysis. Langmuir, 2009; 25(3):1459-65
21. Cavalli R, Akhter AK, Bisazza A, Giustetto P, Trotta F, Vavia P. Nanosponge formulations as oxygen delivery systems. Int J Pharm, 2010; 402(1-2):254-257
22. Longo C, Gambara G, Espina V, Luchini A, Bishop B, Patanarut AS, Petricoin EF 3rd, Beretti F, Ferrari B, Garaci E, De Pol A, Pellacani G, Liotta LA. A novel biomarker harvesting nanotechnology identifies Bak as a candidate melanoma biomarker in serum. Exp Dermatol 2011; 20(1):29-34
23. Amber V, Shailendra S, Swarnalatha S Cyclodextrin based novel drug delivery systems. J Incl Phenom Macrocycl Chem, 2008; 62:23-42
24. Rajeswari C, Alka A, Javed A, Khar R K Cyclodextrins in drug delivery: an update review AAPS pharmSciTech, 2005; 6(2):E329-E357
25. Ramnik S, Nitin B, Jyotsana M, Horemat SN Characterization of Cyclodextrin Inclusion complexes -A Review. J Pharm Sci Tech, 2010; 2(3):171-183
26. Ralph JP, Daniel ES, Alice EV. Targeted nanoparticles that deliver a sustained, specific srelease of Paclitaxel to Irradiated tumors. Cancer Res, 2010; 70:4550-4559
27. Roberta C, Francesco T, Wander T. Cyclodextrinbased nanosponges for drug delivery. J Incl Phenom Macrocycl Chem, 2006; 56: 209-213
28. Trotta F, Cavalli R. Characterization and application of new hyper-cross-linked cyclodextrins. Compos Interface, 2009; 16: 39-48
29. Millan R, Diaz A, Mohallem N, Process of composites preparation between particulate materials and cyclodextrins and their derivatives products thereof. WO 03/041095; 2003
30. Francesco T. Cyclodextrin nanosponges: a new material in supramolecular chemistry Inorganic, Physical and Materials Chemistry Department, University of Torino-an Abstract
31. Ferruti P, Ranucci F, Trotta F, Cavalli R, Fernandez C. Hyperbranched polymers based on cyclodextrins and Poly(amidoamines) for the controlled release of insoluble drugs WO2008/151775 A2; 2008
32. Vavia PR, Swaminattan S, Trota F, Cavalli R Applications of Nanosponges in Drug Delivery XIII International Cyclodextrin Symposium, Turin 14-17, May 2006
33. Thorstenin L, Dominique D. Cyclodextrins and their pharmaceutical applications. int j pharm, 2007; 329:1-11
34. Thorstenin L, Marcus EB. Pharmaceutical applications of Cyclodextrins. 1.Drug solubilization and stabilization. J.Pharm.Sci, 1996; 85(10):1017-1025
35. Roger AR, valentine JS. Pharmaceutical applications of Cyclodextrins. 2. In Vivo Drug Delivery. J.Pharm.Sci, 1996; 85(11):1142-1169
36. Prof. Eva Harth, Nanosponges as Synergistic Drug Delivery Systems to Increase the Efficacy of Treatment. Department of Chemistry, Vanderbilt University, USA.2011
37. Ludovica S, Katia M, Marco D, Carlo R, Francesco T, Valentina S. β-Cyclodextrin-based nanosponges as carriers for 1-MCP in extending the postharvest longevity of carnation cut flowers: an evaluation of different degrees of cross-linking Plant Growth Regul, 2011; 65:505-511
38. Trotta F, Dolci M, Devecchi M, Scariot V, Seglie L. Nanosponges as potential carriers to increase the flowers' vaselife. National Cyclodextrin Symposium, Asti, Italy, 2007
39. Declan F, Santosh Y, Shanti S. Silicon Nanosponge Particles US7569202; 2009
40. Lu Z, Cheng Bo, Hu Yeli, Zhang Youhoung, Zou Guolin. Complexation of resveratrol with cyclodextrins: solubility and antioxidant activity Food Chemistry, 2009; 113(1):17-20
41. Lucas-Abellán C, Fortea I, López-Nicolás JM, Núñez-Delicado E. Cyclodextrins as resveratrol carrier system. Food Chemistry, 2007; 104(1):39-44
42. Szejtli, J. Introduction and general overview of cyclodextrin chemistry. Chem. Rev, 1998; 98:1743-1754
43. Peeters, J., et al. Characterization of the interaction of 2- hydroxypropyl-β-cyclodextrin with itraconazole at pH 2, 4 &7. J Pharm Sci, 2002; 91(6): 1414-1422
44. Erem Bilensoy Cyclodextrins in Pharmaceutics, Cosmetics, and Biomedicine: Current and future industrial applications. John Wiley & Sons, Inc 2011
45. Seglie L, Martina K, Devecchi M, Roggero C, Trotta F, Scariot V. The effects of 1-MCP in cyclodextrin-based nanosponges to improve the vase life of Dianthus caryophyllus cut flowers Postharvest Biol Technol, 2011; 59:200-205
46. Seiler M. Hyperbranched polymers: phase behavior and new applications in the field of chemical engineering. Fluid Phase Eq, 2006; 241:155-174
47. Eva Harth, Nanomedicine: Development of "Nanosponges" as superior sustain delivery systems of diverse biological cargos. Department of Chemistry, Vanderbilt University, USA, 2011
48. Edward CH, Characterisation of Nano-Porous Silicon Particles, Department of Manufacturing and Operations Engineering and Materials and Surface Science Institute, University of Limerick, Ireland, 2010
49. Edward Chadwick and David A. Tanner Characterisation of Porous Silicon Nanosponge Particles. Department of Manufacturing and Operations Engineering and Materials and Surface Science Institute, University of Limerick, Ireland, 2010
50. Nilesh J, Ruchi J, Navneet T, Brham P, Gupta, Deepak K, Jeetendra B, Surendra J Nanotechnology: A Safe And Effective Drug Delivery System. Asian J Phar Cli Res, 2010; 3(3): 159-165
51. Andrea M, Franca C, Luciana M, Fabio G, Giuseppina R, Francesco T, Barbara R, Aldo F, Giovanni G. HR MAS NMR, powder XRD and raman spectroscopy study of inclusion phenomena in βCD nanosponges. J Incl Phenom Macrocycl Chem, 2011; 69:403-409
52. DeQuan L, Min M. Nanosponges for water purification. Clean products and processes, 2000; 2: 112-116
53. Arkas M, Allabashi R, Tsiourvas D, Mattausch EM, Perfler R. Organic/inorganic hybrid filters based on dendritic and cyclodextrin nanosponges for the removal of organic pollutants from water. Environ Sci Technol, 2006; 40(8):2771-2777
54. Di Nardo G, Roggero C, Campolongo S, Valetti F, Trotta F, Gilardi G. Catalytic properties of catechol 1,2-dioxygenase from Acinetobacter radioresistens S13 immobilized on nanosponges Dalton Trans, 2009; 33:6507-6512
55. Duchene D, Vaution C, Glomot F. Cyclodextrin, Their Value in pharmaceutical Technology. Drug Dev Ind Pharm, 1998; 12(11-13): 2193-2215.
56. Marzouqi A.H.A, Shehatta I, Jobe B, Dowaidar A. Phase solubility and inclusion complex of Itraconazole with ß-cyclodextrin using supercritical carbon dioxide. J Pharm Sci, 2006; 95(2): 292-304.
57. Tayade PT, Vavia PP. Inclusion complexes of Ketoprofen with β- cyclodextrins: Oral pharmacokinetics of Ketoprofen in human. Indian J Pharm Sci, 2006; 68(2):164-170.
58. Noriaki F, Seiji I, Saburo N. Advances in physical chemistry and pharmaceutical applications of cyclodextrins. Pure Appl Chem, 2008; 80(7):1511-1524.
59. Arun R, Ashokkumar CK, Sravanthi VVNSS Cyclodextrins as drug carrier Molecule: A Review. Sci Pharm, 2008; 76: 567-598.
60. Mark ED, Marcus EB. Cyclodextrin-based Pharmaceutics: past, present and future. Drug Discovery, 2004; 3:1023-1035.
61. Mei D, Xu X, Jia S, Shaozhi F, MaLing G, Feng L, ZhiYong Q. Preparation of camptothecinloaded PCEC microspheres for the treatment of colorectal peritoneal carcinomatosis and tumor growth in mice. J canlet, 2011; 312:189-196.
62. Amri A, Chaumeil JC, Sfar S, Charrueau C Administration of resveratrol: what formulation solutions to bioavailability limitations?. J Control release, 2011; 09(083):1-12.
63. Srikanth MV, Muralimohanbabu GV, Sreenivasa rao N, Sunil SA, Balaji S, Ramanamurthy KV Dissolution rate enhancement of poorly soluble bicalutamide using β-cyclodextrin inclusion complexation. Int J Pharm Ph Sci, 2010; 2(1): 191-198.
64. James B, Stefan P. Some important considerations in the use of cyclodextrins. Pharm res, 1999; 16(12):1796-1798.
65. Thorstein L, Robert O F. cyclodextrins in solid dosage forms. Faculty of Pharmacy, University of Iceland, and Senior Partner, Strategic Business Solutions.
66. Abd-Elgawad R, Shimaa E. Electrochemistry of Cyclodextrin Inclusion Complexes of Pharmaceutical Compounds The Open Chemical and Biomedical Methods Journal, 2010; 3: 74-85
67. Gharib Naseri N, Ashnagar A, Husseini F. Study of the Inclusion Complexation of Piroxicam-β- Cyclodextrin and Determination of the Stability Constant (K) by UV-Visible Spectroscopy Scientia Iranica, 2007; 14(4): 308-315
68. Narender Reddy M, Rehana T, Ramakrishna S, Chowdary KPR, Prakash VD. β-Cyclodextrin Complexes of Celecoxib: Molecular-Modeling, Characterization, and Dissolution Studies. AAPS PharmSci, 2004; 6(1): 1-9.